Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results ...
Clear strategy & focus: Atossa is concentrating capital on programs and data packages that can enable future regulatory submissions and potential commercialization. Compelling thesis for new investors ...
SEATTLE – Atossa Therapeutics, Inc., a biopharmaceutical company with a market capitalization of $98.77 million, has been notified by The Nasdaq Stock Market LLC that it is currently not meeting the ...
Type C FDA Meeting Requested, Update Expected by Year-End 2025 SEATTLE, Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (ATOS) (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has ...
The MarketWatch News Department was not involved in the creation of this content. Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development ...
SEATTLE, Nov. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results